Keywords
Diabetes mellitus
Hyperglycemia
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze corticosteroid-induced diabetes mellitus. Methods: This is an integrative review, through searches in the scientific databases PubMed, BVS and LILACS, where 9 articles were selected in PubMed, 6 articles in VHL, 1 article in LILACS, totaling 16 articles. Results: Diabetes mellitus is a chronic disease characterized as a heterogeneous group of changes at the metabolic level, which are the result of sustained hyperglycemia, caused mainly by deficits in insulin action, in the secretion of this hormone or, in some situations, of both defects. Thus, diabetes and hypertension were the most frequent cardiometabolic toxicities based on exposure patterns to the various glucocorticoids, according to the underlying disease, whereas inhaled corticosteroids and dispensed inhaled ß-agonists were associated with a higher increased risk of type 1 diabetes after adjusting for other anti-asthmatic medications, asthma, gender, and decade of birth. Final considerations: Therefore, the use of corticosteroids in a wide spectrum of diseases, depending on the dose, exposure time and severity of the underlying disease, can induce the onset of diabetes mellitus.
References
ABBAS N, et al. Greater illnes severity characterises steroid diabetes following acute hospitalisation. Clin Med (London), 2019; 19 (1)
BLOECHLIGER M. et al. Adverse events profile of oral corticosteroids among asthma patiente in the UK: cohort study with a nested case-control analysis. Respir Res, 2018; 19(1).
BRUNO FJ; FILÁRTIGA, E. O. Incidence of hyperglycemia in patients with corticosteroid therapy. Rev. virtual. Soc. Parag. Med. Int, 2018; 5(2).
CAMPOS HS. Corticoterapia. Arq Asma Alerg Imunol, 2018; 2(3).
CARDOZA-JIMÉNEZ K, et al. Daily glucose variation influenced by the use of corticosteroides in COVID-19 patients treated in Lima-Peru. Diabetes Metab Syndr, 2021; 15(4).
DUBE S, et al. Glucocorticoid excess increases hepatic 11β-HSD-1 activity in humans: implications in steroid-induced diabetes. J Clin Endocrinol Metab, 2015; 100(11): 4155-62.
HORTON DB, et al. Oral glucocorticoids and incident treatment of diabetes mellitus, hypertersion and venous thromboembolismo in children. Am J Epidemiol, 2021; 190 (3): 403-412.
International Diabetes Federation. IDF Diabetes Atlas. 8ª ed. International Diabetes Federation; 2017: 145.
ITOH A, et al. Time-dependent changes in insulin requirement for maternal glycemic control during antenatal corticosteroid therapy in women with gestational diabetes: a retrospective study. Endocr J, 2016; 63(1):101-4.
MALTA DC, et al. Prevalência de diabetes mellitus determinada pela hemoglobina glicada na população adulta brasileira, Pesquisa Nacional de Saúde. Rev Bras Epidemol, 2019; 22(2).
MATSUMOTO N, et al. Prevalence and risk factors of diabates mellitus in patients with autoimmune hepatits. Intern Med, 2016; 55(8):879-85.
MCDONNEL M, et al. High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning. BMJ Open Gastroenterol, 2020 7(1).
METSALA J, et al. Use of antiasthmatic drugs and the risk of type 1 diabetes in children: a nationwide case-cohort study, Am J Epidemiol, 2020; 189 (8): 779-787.
MIYAWAKI Y, et al. An open-label pilot study on preventing glucocorticoide-induced diabetes mellitus with linagliptin. J Med Case Rep, 2018; 12(1): 288.
MOURI M; BADIREDDY M. Hyperglycemia. StatPearls, 2022.
NEVES FS. Dez regras práticas para a terapia com corticoides nas doenças inflamatórias em adultos. Bol Cursuo Med UFSC, 2018; 4(10).
PINTO FR; DIAS LFR.; NEUMANN, K. R. S. O uso prolongado de fármacos glicocorticoides e o desenvolvimento da síndrome de cushing. Revista Multidisciplinar do Nordeste Mineiro, 2018.
PRICE DB, et al. Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. NPJ Prim Care Respir Med, 2019; 29(1): 38.
ROBERTS A, et al. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med, 2018; 35(8): 1011-1017.
SALVIANO CMT, et al. Hiperglicemia induzida por corticosteroides: uma revisão integrativa. Visão Acadêmica, 2020; 21(1).
SCHMIDT AM. Highlighting diabetes – the epidemic continues. Arterioscler Thromb Vasc Biol, 2018; 38(1).
SHAHARIR SS, et al. Steroid-induced diabetes mellitus in systemc lupus erythematosus patients: analysis from a Malasyan multi-ethnic lupus cohort. Int J Rheum Dis, 2015; 18(5): 541-7.
SOCIEDADE BRASILEIRA DE DIABETES. Diretrizes da sociedade brasileira de diabetes 2019-2020. São Paulo: SBD, 2019.
STALLBERG B, et al. Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients. NPJ Prim Care Respir Med, 2020; 30(1): 47.
TANABE K, et al. Risk factors of hyperglycmia after nerve blockade with dexamethasone in non-diabetes mellitus patients: a cohort study. Pain Physician, 2021; 24(1):87-93.
TAVARES FRS, et al. Efeitos deletérios do uso crônico de corticoides: uma abordagem do desenvolvimento de síndrome de cushing. Research. Society and Development, 2021; 10(4).
TUOHY J, et al. Maternal and neonatal glycaemic control after antenatal corticosteroid administration in women with diabetes in pregnancy: a retrospective cohort study. PLoS One, 2021; 16(2).
YEH J-H, et al. Risk of diabetes mellitus among patients with myasthenia gravis. Acta Neurol Scand, 2015; 132(2): 132-8.